A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients.
Changchun Deng
No relevant relationships to disclose
Jennifer Effie Amengual
No relevant relationships to disclose
Marshall T. Schreeder
No relevant relationships to disclose
Sean Clark-Garvey
No relevant relationships to disclose
Molly Patterson
No relevant relationships to disclose
Hari Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Owen A. O'Connor
No relevant relationships to disclose